BRPI0409250B8 - Composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar - Google Patents

Composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar

Info

Publication number
BRPI0409250B8
BRPI0409250B8 BRPI0409250A BRPI0409250A BRPI0409250B8 BR PI0409250 B8 BRPI0409250 B8 BR PI0409250B8 BR PI0409250 A BRPI0409250 A BR PI0409250A BR PI0409250 A BRPI0409250 A BR PI0409250A BR PI0409250 B8 BRPI0409250 B8 BR PI0409250B8
Authority
BR
Brazil
Prior art keywords
receptor agonist
sugar alcohol
solid pharmaceutical
pharmaceutical compositions
solid
Prior art date
Application number
BRPI0409250A
Other languages
English (en)
Portuguese (pt)
Inventor
Edward Royce Alan
Colleen Ruegger
Madhusudhan Pudipeddi
Masaki Sasaki
Tokuhiro Tamura
Tomoyuki Oomura
Original Assignee
Mitsubishi Pharma Corp
Mitsubishi Tanabe Pharma Corp
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0409250(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Pharma Corp, Mitsubishi Tanabe Pharma Corp, Novartis Ag filed Critical Mitsubishi Pharma Corp
Publication of BRPI0409250A publication Critical patent/BRPI0409250A/pt
Publication of BRPI0409250B1 publication Critical patent/BRPI0409250B1/pt
Publication of BRPI0409250B8 publication Critical patent/BRPI0409250B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BRPI0409250A 2003-04-08 2004-04-06 Composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar BRPI0409250B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08
US60/461,215 2003-04-08
PCT/EP2004/003656 WO2004089341A1 (en) 2003-04-08 2004-04-06 Organic compounds

Publications (3)

Publication Number Publication Date
BRPI0409250A BRPI0409250A (pt) 2006-03-28
BRPI0409250B1 BRPI0409250B1 (pt) 2017-07-11
BRPI0409250B8 true BRPI0409250B8 (pt) 2022-01-18

Family

ID=32326722

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409250A BRPI0409250B8 (pt) 2003-04-08 2004-04-06 Composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar

Country Status (41)

Country Link
US (11) US20060275357A1 (OSRAM)
EP (5) EP1613288B1 (OSRAM)
JP (3) JP5495467B2 (OSRAM)
KR (3) KR101367574B1 (OSRAM)
CN (2) CN101797241B (OSRAM)
AR (3) AR043987A1 (OSRAM)
AT (3) AT501681B1 (OSRAM)
AU (1) AU2004228929B2 (OSRAM)
BE (2) BE1015972A5 (OSRAM)
BR (1) BRPI0409250B8 (OSRAM)
CA (2) CA2521325C (OSRAM)
CL (2) CL2004000745A1 (OSRAM)
CY (3) CY1110260T1 (OSRAM)
DE (4) DE202004021680U1 (OSRAM)
DK (2) DK2316431T3 (OSRAM)
EC (1) ECSP056090A (OSRAM)
ES (3) ES2228282B1 (OSRAM)
FR (2) FR2854073B1 (OSRAM)
GB (1) GB2400318B (OSRAM)
GR (1) GR1005052B (OSRAM)
HR (3) HRP20100601B1 (OSRAM)
HU (2) HUE028247T2 (OSRAM)
IL (3) IL170888A (OSRAM)
IS (2) IS2682B (OSRAM)
IT (1) ITMI20040682A1 (OSRAM)
LU (1) LU91867I2 (OSRAM)
MA (1) MA27729A1 (OSRAM)
MX (1) MXPA05010860A (OSRAM)
MY (1) MY141249A (OSRAM)
NO (4) NO329332B1 (OSRAM)
NZ (3) NZ592339A (OSRAM)
PE (5) PE20050396A1 (OSRAM)
PL (2) PL2316431T3 (OSRAM)
PT (1) PT1613288E (OSRAM)
RU (5) RU2358716C2 (OSRAM)
SG (1) SG175449A1 (OSRAM)
SI (2) SI1613288T1 (OSRAM)
TN (1) TNSN05256A1 (OSRAM)
TW (1) TWI332847B (OSRAM)
WO (1) WO2004089341A1 (OSRAM)
ZA (1) ZA200507394B (OSRAM)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1773307E (pt) * 2004-07-30 2015-01-14 Novartis Ag Formulações de compostos à base de 2-amino-1,3- propanodiol
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
CA2620554C (en) * 2005-09-09 2013-12-17 Novartis Ag Treatment of autoimmune diseases
KR101434522B1 (ko) 2005-11-09 2014-08-26 오닉스 세라퓨틱스, 인크. 효소 저해를 위한 화합물
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
US7691852B2 (en) 2006-06-19 2010-04-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
CA2953372C (en) * 2006-09-26 2020-06-23 Novartis Ag Pharmaceutical composition comprising an s1p receptor modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
MX351987B (es) * 2007-03-29 2017-11-03 Daiichi Sankyo Co Ltd Composicion farmaceutica.
RS54847B2 (sr) 2007-10-04 2019-09-30 Onyx Therapeutics Inc Inhibitori kristalne peptid epoksi keton proteaze i sinteza aminokiselinskih keto-epoksida
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
AR068986A1 (es) 2007-10-12 2009-12-23 Novartis Ag Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p)
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
KR101718639B1 (ko) 2008-03-17 2017-03-21 액테리온 파마슈티칼 리미티드 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생
CA2728436C (en) * 2008-06-20 2016-07-26 Merck Patent Gmbh Directly compressible and rapidly disintegrating tablet matrix
SG10201406263SA (en) 2008-06-20 2015-02-27 Novartis Ag Paediatric compositions for treating multiple sclerosis
JP5718231B2 (ja) * 2008-09-04 2015-05-13 カーギル インコーポレイテッド エリスリトールの打錠
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
AU2013100532B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
AU2009315735B2 (en) 2008-11-11 2013-01-10 Novartis Ag Salts of fingolimod
PT2356090T (pt) * 2008-11-11 2017-10-16 Novartis Ag Formas cristalinas de fingolimod, hcl
MY150973A (en) 2008-12-17 2014-03-31 Daiichi Sankyo Co Ltd Method for producing diamine derivative
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
CN102348688B (zh) 2009-03-10 2014-07-09 第一三共株式会社 用于制备二胺衍生物的方法
EP2407450B1 (en) 2009-03-13 2015-04-22 Daiichi Sankyo Company, Limited Method for producing optically active diamine derivative
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
ES2605034T3 (es) * 2009-06-18 2017-03-10 Daiichi Sankyo Company, Limited Composición farmacéutica con solubilidad mejorada
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
MA34133B1 (fr) 2010-03-01 2013-04-03 Onyx Therapeutics Inc Composes pour inhibiteurs de l'immunoproteasome
HUE031059T2 (en) 2010-03-19 2017-06-28 Daiichi Sankyo Co Ltd Procedure for improving anticoagulant administration
CA2793413C (en) 2010-03-19 2015-11-24 Daiichi Sankyo Company, Limited Crystal form of edoxaban tosylate monohydrate and method of producing same
EP2560619A2 (en) * 2010-04-22 2013-02-27 Ratiopharm GmbH A method of preparing an oral dosage form comprising fingolimod
JP5780657B2 (ja) 2010-07-02 2015-09-16 第一三共株式会社 光学活性ジアミン誘導体の塩の製造方法
US9266816B2 (en) 2010-11-25 2016-02-23 Shilpa Medicare Limited Fingolimod polymorphs and their processes
BR112013017302B1 (pt) 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
ES2662373T3 (es) 2011-01-19 2018-04-06 Pathologica, Llc. Formas de dosificación farmacéutica oral de liberación controlada que comprenden MGBG
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EA028950B1 (ru) 2011-08-01 2018-01-31 Тева Фармасьютикал Индастриз Лтд. Способ получения фармацевтических композиций, содержащих финголимод
ES2673182T3 (es) 2011-08-10 2018-06-20 Daiichi Sankyo Company, Limited Composición farmacéutica que contiene un derivado de diamina
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
CN109432073A (zh) 2013-01-08 2019-03-08 帕萨罗杰卡有限公司 Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
ES2733920T3 (es) * 2013-04-26 2019-12-03 Univ Kyoto Composición que comprende un agonista del receptor 1 de esfingosina-1-fosfato para inhibir la formación y/o el aumento de tamaño de un aneurisma cerebral o para reducirlo
ES2770500T3 (es) * 2013-05-13 2020-07-01 Synthon Bv Composición farmacéutica que comprende fingolimod
WO2015015254A1 (en) * 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN106794159A (zh) * 2014-08-22 2017-05-31 广东东阳光药业有限公司 一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
AU2016209466A1 (en) * 2015-01-20 2017-08-10 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
WO2022015348A1 (en) 2020-07-16 2022-01-20 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection
EP4248958A3 (en) * 2021-01-28 2024-01-03 Priothera SAS Methods of treatment with s1p receptor modulators

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
DE122011100012I1 (de) 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
WO1996006068A1 (en) 1994-08-22 1996-02-29 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and medicinal use thereof
CA2213989C (en) 1995-12-28 2007-05-29 Yoshitomi Pharmaceutical Industries Ltd. External preparation for topical administration
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
KR20000075745A (ko) * 1997-02-27 2000-12-26 가마후라 아키오 의약 조성물
IL155065A (en) * 1997-04-04 2004-01-04 Mitsubishi Pharma Corp History - 2 Aminopropene - 1, 3 - Diol and Pharmaceutical Preparations Containing Them
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
KR20020027463A (ko) * 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
CN1267429C (zh) 2000-07-13 2006-08-02 三共株式会社 氨基醇衍生物
CA2421893A1 (en) 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
EP1377593B1 (en) 2001-03-26 2005-12-28 Novartis AG 2-amino-propanol derivatives
US7521192B2 (en) * 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
JPWO2003020313A1 (ja) 2001-09-04 2004-12-16 小野薬品工業株式会社 スフィンゴシン−１−リン酸受容体調節剤からなる呼吸器疾患治療剤
US6963012B2 (en) 2001-09-27 2005-11-08 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
CA2461212C (en) 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
WO2003062252A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
DE60330047D1 (en) 2002-01-18 2009-12-24 Merck & Co Inc "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten"
EP1772145B1 (en) * 2004-07-16 2011-03-23 Kyorin Pharmaceutical Co., Ltd. Method of effectively using medicine and method concerning prevention of side effect

Also Published As

Publication number Publication date
CY1110260T1 (el) 2014-04-09
HK1091114A1 (en) 2007-01-12
CY1117071T1 (el) 2017-04-05
JP2011006461A (ja) 2011-01-13
BRPI0409250A (pt) 2006-03-28
ZA200507394B (en) 2007-03-28
RU2005134173A (ru) 2006-09-10
AU2004228929B2 (en) 2008-02-07
DE102004016947A1 (de) 2004-10-21
IL197578A (en) 2015-10-29
SI1613288T1 (sl) 2009-04-30
US20200237690A1 (en) 2020-07-30
EP1613288A1 (en) 2006-01-11
CN101797241B (zh) 2013-03-27
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
ATE414508T1 (de) 2008-12-15
RU2358716C2 (ru) 2009-06-20
CN1767819A (zh) 2006-05-03
DE122011100047I1 (de) 2011-12-15
JP2013177404A (ja) 2013-09-09
MY141249A (en) 2010-03-31
US20080311188A1 (en) 2008-12-18
US20140255497A1 (en) 2014-09-11
IL170888A (en) 2010-06-16
BRPI0409250B1 (pt) 2017-07-11
PE20150676A1 (es) 2015-05-17
LU91867I9 (OSRAM) 2019-01-03
AT504853A2 (de) 2008-08-15
CY2011013I2 (el) 2014-04-09
CA2521325C (en) 2010-09-14
JP2004307506A (ja) 2004-11-04
CN1767819B (zh) 2010-07-28
LU91867I2 (fr) 2011-11-08
ECSP056090A (es) 2006-03-01
AT501681B1 (de) 2012-04-15
CA2707750A1 (en) 2004-10-21
NO2011016I1 (no) 2011-09-19
MA27729A1 (fr) 2006-01-02
KR20120101148A (ko) 2012-09-12
PT1613288E (pt) 2009-02-25
HUE028247T2 (en) 2016-12-28
PE20131352A1 (es) 2013-11-14
GR1005052B (el) 2005-11-30
AR078781A2 (es) 2011-11-30
US20220031609A1 (en) 2022-02-03
KR101367574B1 (ko) 2014-02-25
WO2004089341A1 (en) 2004-10-21
EP1613288B1 (en) 2008-11-19
PE20090743A1 (es) 2009-07-17
NZ542622A (en) 2009-01-31
ITMI20040682A1 (it) 2004-07-06
JP5543298B2 (ja) 2014-07-09
AU2004228929A1 (en) 2004-10-21
FR11C0036I2 (fr) 2023-12-29
US8324283B2 (en) 2012-12-04
AR043987A1 (es) 2005-08-17
SG175449A1 (en) 2011-11-28
IS8885A (is) 2010-02-25
HRP20100601A2 (hr) 2011-03-31
GB0407819D0 (en) 2004-05-12
SI2316431T1 (sl) 2016-04-29
PL1613288T3 (pl) 2009-07-31
NO334116B1 (no) 2013-12-16
NZ586280A (en) 2011-12-22
ES2556947T3 (es) 2016-01-21
US20190175527A1 (en) 2019-06-13
KR20050121712A (ko) 2005-12-27
NO20100250L (no) 2006-01-09
PE20130200A1 (es) 2013-03-09
NO20055231D0 (no) 2005-11-07
BE2011C030I2 (OSRAM) 2023-03-07
CY2011013I1 (el) 2014-04-09
IL242037A0 (en) 2015-11-30
RU2009105403A (ru) 2010-08-27
CL2004000745A1 (es) 2005-02-11
RU2475236C2 (ru) 2013-02-20
MXPA05010860A (es) 2006-05-25
NO20131287L (no) 2006-01-09
CN101797241A (zh) 2010-08-11
KR20110005320A (ko) 2011-01-17
EP2008650A2 (en) 2008-12-31
US20130108675A1 (en) 2013-05-02
GR20040100121A (el) 2004-12-17
GB2400318A (en) 2004-10-13
DE602004017847D1 (de) 2009-01-02
TW200503784A (en) 2005-02-01
DK2316431T3 (en) 2016-01-11
PE20050396A1 (es) 2005-07-05
ES2228282B1 (es) 2006-02-16
CA2521325A1 (en) 2004-10-21
DE202004021680U1 (de) 2010-04-22
AR078782A2 (es) 2011-11-30
HRP20100600A2 (hr) 2011-03-31
EP2008650A3 (en) 2011-04-27
NO335120B1 (no) 2014-09-22
IS2682B (is) 2010-10-15
RU2010146697A (ru) 2012-05-27
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
ES2228282A1 (es) 2005-04-01
HRP20050886B1 (en) 2011-01-31
IS8114A (is) 2005-11-01
EP2316431B1 (en) 2015-09-30
US20110105620A1 (en) 2011-05-05
ES2320767T3 (es) 2009-05-28
IL197578A0 (en) 2011-07-31
US20140011885A1 (en) 2014-01-09
US20060275357A1 (en) 2006-12-07
TNSN05256A1 (en) 2007-07-10
NZ592339A (en) 2012-09-28
RU2475237C2 (ru) 2013-02-20
AT501681A1 (de) 2006-10-15
FR11C0036I1 (fr) 2011-10-14
NO2011016I2 (no) 2012-08-27
HRP20050886A2 (en) 2006-11-30
IE20040246A1 (en) 2004-12-15
GB2400318B (en) 2005-08-10
US20170290787A1 (en) 2017-10-12
DK1613288T3 (da) 2009-03-23
NO329332B1 (no) 2010-09-27
HUS1100016I1 (hu) 2016-08-29
EP2319502A1 (en) 2011-05-11
HK1155647A1 (en) 2012-05-25
JP5495467B2 (ja) 2014-05-21
HRP20100601B1 (hr) 2016-12-02
EP2769713A1 (en) 2014-08-27
FR2854073B1 (fr) 2008-03-14
FR2854073A1 (fr) 2004-10-29
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
RU2010147000A (ru) 2012-08-10
RU2012148593A (ru) 2014-05-20
US20090203798A1 (en) 2009-08-13
TWI332847B (en) 2010-11-11

Similar Documents

Publication Publication Date Title
BRPI0409250B8 (pt) Composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
DK1185253T3 (da) Oralt præparat til indgivelse af en fast kombination af tramadol og diclofenac
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BRPI0413676A (pt) composto, e, composição farmacêutica
DE602004005564D1 (de) Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
WO2008060546A3 (en) Oral formulations
NO20064808L (no) Orale matrixformuleringer med licarbazepin
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
AU2003244259A1 (en) Oral injectable pharmaceutical composition comprising florfenicol as an active ingredient
ITRM20030074A0 (it) Formulazioni semisolide a rilascio immediato intese per la somministrazione orale di farmaci.
EA200602199A1 (ru) Композиции, содержащие глюкозаминогликан и нестероидное противовоспалительное средство
HK1071685B (en) Pharmaceutical composition comprising an s1p receptor agonist
TNSN06299A1 (en) Oral matrix formulations comprising licarbazepine
ATE429905T1 (de) Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung
WO2005037247A3 (en) Oral matrix formulations of doxazosin

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PARA:INT.CI. A61K31/135 " "A61K31/137 "31/00

Ipc: A61K 31/135 (2011.01), A61K 31/137 (2011.01), A61K

Free format text: PARA:INT.CI. A61K31/135; A61K31/137; A61K45/00; A61K45/06; A61K47/12; A61K47/26; A61K9/20; A61K9/36; A61K9/48; A61K9/62; A61P29/00; A61P31/00; A61P31/12; A61P37/00; A61P37/02; A61P37/06; A61K31/135; A61K31/137; A61K45/00; A61K47/12; A61K47/26; A61K9/20; A61K9/30; A61K9/48; A61K9/52; A61P29/00; A61P31/00; A61P37/00

Ipc: A61K 31/135 (2011.01), A61K 31/137 (2011.01), A61K

B65X Notification of requirement for priority examination of patent application
B65Z Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117)

Free format text: NEGADO O EXAME PRIORITARIO DO PEDIDO DE PATENTE UMA VEZ QUE NAO FOI ATENDIDO O DISPOSTO NO PARAGRAFO 2O, ART.1O DA RESOLUCAO 080/13.

B65X Notification of requirement for priority examination of patent application
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: NOVARTIS AG (CH) , MITSUBISHI PHARMA CORPORATION (

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 20130072954/RJ, DE 29/08/2013, E NECESSARIO APRESENTAR DOCUMENTACAO QUE EVIDENCIE A ALTERACAO DE NOME SOLICITADA, POIS OS DOCUMENTOS APRESENTADOS MOSTRAM UMA INCORPORACAO POR ABSORCAO.

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH) , MITSUBISHI TANABE PHARMA CORPOR

B150 Others concerning applications: publication cancelled [chapter 15.30 patent gazette]

Free format text: REFERENTE AO DESPACHO 15.24 PUBLICADO NA RPI NO 2251 DE 25/02/2014.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO NO NPRJ020130078305 DE 25/09/2013, COM BASE NO ART. 219, II DA LEI DA PROPRIEDADE INDUSTRIAL, UMA VEZ QUE HOUVE A DESISTENCIA DA SOLICITACAO DE EXAME PRIORITARIO ATRAVES DOS PROTOCOLOS RJ 860140048882 DE 10/04/2014 E RJ 860140173031 DE 15/10/2014.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/07/2017, OBSERVADAS AS CONDICOES LEGAIS.

B25E Requested change of name of applicant rejected
B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent
B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent
B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.001988/2018-52 TRIBUNAL REGIONAL FEDERAL DA 2A REGIAO 31A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO0005369-50.2018.4.02.0000 AGRAVANTE: EMS S.A. AGRAVADO: INPI - INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL, NOVARTIS AG E MITSUBISHI TANABE PHARMA DECISAO: ANTE O EXPOSTO, DEFIRO A TUTELA DE URGENCIA RECURSAL, PARA SUSPENDER OS EFEITOS DA PI0409250-3, INTER PARTES, NOS TERMOS DO ART. 932 II, DO CPC DE 2015, ATE A DECISAO FINAL DESTE AGRAVO DE INSTRUMENTO.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.001988/2018-52 SECAO JUDICIARIA DO RIO DE JANEIRO 31A VARA FEDERAL DO RIO DE JANEIRO PROCESSO:NO: 0219305-21.2017.4.02.5101 AUTOR: SEM S/AREU: NOVARTIS AG E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI DECISAO: DEFIRO O REQUERIMENTO DE TUTELA DE URGENCIA PARA SUSPENDER OS EFEITOS DA PATENTE PI 0409250-3 ENTRE AS PARTES.AFASTO, POR INCOMPETENCIA, A ANALISE DOS REQUERIMENTOS DE QUE AS EMPRESAS RES OU OUTRAS DE SEU GRUPO ECONOMICO DEIXEM DE OBSTAR AS ATIVIDADES DA DEMANDANTE, E QUE A AUTORA NAO SEJA TOLHIDA POR TERCEIROS DE VIR A COMERCIALIZAR SEU MEDICAMENTO. A ANALISE DESSAS QUESTOES DEVE SER FEITA EM AMBITO DA JUSTICA ESTADUAL, QUE DEVE PASSAR A CONSIDERAR AGORA A SUSPE

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI NO 52400.001988/2018-52 SECAO JUDICIARIA DO RIO DE JANEIRO - 31A VARA FEDERAL DO RIO DE JANEIRO PROCEDIMENTO COMUM NO 0219305-21.2017.4.02.5101/RJ NUP: 00408.033558/2019-15 AUTOR: EMS S/A REU: NOVARTIS AG REU: INPI - INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL DECISAO:DIANTE DO EXPOSTO, JULGO PROCEDENTE O PEDIDO, PARA DECLARAR A NULIDADE DA PATENTE PI0409250-3, NOS TERMOS DO ART. 487, I, DO CPC. CONCEDO A TUTELA PROVISORIA DE URGENCIA PARA DETERMINAR A SUSPENSAO DOS EFEITOS DA PI0409250-3, ATE O TRANSITO EM JULGADO DA SENTENCA, PELOS FUNDAMENTOS ACIMA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/04/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.